CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation. Leronlimab is a humanized monoclonal antibody that is a once-a-week subcutaneous injection that can also be administered intravenously. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. This mechanism of action of binding competitively to the CCR5 receptor differentiates leronlimab from all other CCR5 antagonists.
We're tracking CytoDyn's market expansion
How CytoDyn's international expansion compares to its competitors
CytoDynYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 CytoDynYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
CytoDyn initiates expanded access program for triple-negative breast cancer patients, advancing leronlimab, a first-in-class humanized monoclonal antibody.
CytoDyn reports encouraging survival data for leronlimab in metastatic triple-negative breast cancer patients, indicating potential therapeutic benefits.
CytoDyn has completed enrollment in its Phase 2 metastatic colorectal cancer study with over 60 patients across seven clinical sites in the United States.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about CytoDyn's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
